Fifty-three patients with advanced cancer were studied prospectively for 6 months to assess whether the site and method of chemotherapy administration influence levels of anxiety and depression. Patients received chemotherapy either at home or in hospital. Cases of clinical anxiety (36%) and depression (27%) were highest in the hospital treated group during the middle period of therapy. Patients treated at home had a lower psychiatric morbidity for anxiety (21%) and depression (21%) at the same period. There was no statistically significant difference in the mean scores on anxiety and depression between the groups. Overall, anxiety was more prevalent than depression. This study indicates that a minority of patients with advanced cancer treated by chemotherapy experience measureable psychiatric morbidity. Counselling services should be provided for these women throughout treatment, not just at the outset.